Recorded fact · drug.label_indication
drug.label_indication for abemaciclib|metastatic-breast-cancer
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 64895e39 resolves to.
The record
| Fact id | 64895e39eae99d4fee943668 |
|---|---|
| Entity | drug: abemaciclib|metastatic-breast-cancer |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260713 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: f5df3dd6726ff66969901d6042a725f641f419eeef83d8b651325a84cd93503e.
The value
{
"ingredient": "ABEMACICLIB",
"conditionId": "metastatic-breast-cancer",
"conditionName": "Metastatic Breast Cancer",
"matchedAlias": "metastatic breast cancer",
"context": "indication",
"brand": "Verzenio",
"identifiedVia": "product_elements",
"extractor": 5,
"labelSetId": "be4bc0de-0fdc-4d46-8d25-be43c79e6a06",
"labelEffectiveTime": "20260713",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: 94245da4e8be801d42ab8422c3dcb9624445578295e2d7a7d68b03359ee31f56.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.